Search research articles
Contact Us
Filters
Showing results (81-90 of 105) with videos related to
Page
of 11
Sort By:
The New England Journal of Medicine
|
June 7, 2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul E Goss, James N Ingle, Kathleen I Pritchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2020
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
E Shelley Hwang, Terry Hyslop, Laura H Hendrix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Sibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
Ian Krop, Vandana Abramson, Marco Colleoni, et al.
The Lancet. Oncology
|
May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Breast (Edinburgh, Scotland)
|
March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
JAMA Oncology
|
December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Breast Cancer Research : BCR
|
July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing, Nancy U Lin, Matthew A Maurer, et al.
Blood Cancer Journal
|
July 19, 2022
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng, et al.
Breast Cancer Research and Treatment
|
February 21, 2013
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Miguel Martín, Aleix Prat, Alvaro Rodríguez-Lescure, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 105) with videos related to
Sort By:
Page
of 11
The New England Journal of Medicine
|
June 7, 2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul E Goss, James N Ingle, Kathleen I Pritchard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2020
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)
E Shelley Hwang, Terry Hyslop, Laura H Hendrix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2024
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
Sibylle Loibl, Jacek Jassem, Amir Sonnenblick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
Ian Krop, Vandana Abramson, Marco Colleoni, et al.
The Lancet. Oncology
|
May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Breast (Edinburgh, Scotland)
|
March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
JAMA Oncology
|
December 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Nancy U Lin, Rashmi K Murthy, Vandana Abramson, et al.
Breast Cancer Research : BCR
|
July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing, Nancy U Lin, Matthew A Maurer, et al.
Blood Cancer Journal
|
July 19, 2022
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng, et al.
Breast Cancer Research and Treatment
|
February 21, 2013
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Miguel Martín, Aleix Prat, Alvaro Rodríguez-Lescure, et al.
Page
of 11